Mark Boldrin

5.0k total citations · 2 hit papers
22 papers, 3.5k citations indexed

About

Mark Boldrin is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology and Molecular Biology. According to data from OpenAlex, Mark Boldrin has authored 22 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Endocrinology, Diabetes and Metabolism, 13 papers in Pharmacology and 8 papers in Molecular Biology. Recurrent topics in Mark Boldrin's work include Diabetes Treatment and Management (14 papers), Pharmacology and Obesity Treatment (13 papers) and Diabetes Management and Research (8 papers). Mark Boldrin is often cited by papers focused on Diabetes Treatment and Management (14 papers), Pharmacology and Obesity Treatment (13 papers) and Diabetes Management and Research (8 papers). Mark Boldrin collaborates with scholars based in United States, Switzerland and United Kingdom. Mark Boldrin's co-authors include Lars Sjöström, Jonathan Hauptman, Jarl Torgerson, Aila Rissanen, H. P. F. Koppeschaar, Michel Krempf, Alain Golay, Teis Andersen, Sarah Hampl and Jean‐Pierre Chanoine and has published in prestigious journals such as The Lancet, JAMA and Diabetes Care.

In The Last Decade

Mark Boldrin

22 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study

2004 1.3k citations Jarl Torgerson, Jonathan Hauptman et al. Diabetes Care profile →
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients

1998 865 citations Lars Sjöström, Aila Rissanen et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Boldrin United States	16	2.2k	1.9k	1.3k	582	491	22	3.5k
Jonathan Hauptman United States	14	3.0k 1.4×	2.0k 1.1×	1.7k 1.3×	630 1.1×	383 0.8×	20	4.2k
Adamandia D. Kriketos Australia	21	307 0.1×	910 0.5×	1.6k 1.3×	520 0.9×	535 1.1×	28	3.5k
Kerstin Kempf Germany	27	420 0.2×	716 0.4×	776 0.6×	193 0.3×	310 0.6×	69	2.1k
Michael EJ Lean United Kingdom	12	446 0.2×	743 0.4×	413 0.3×	226 0.4×	355 0.7×	22	1.6k
Christine Beebe United States	13	168 0.1×	1.2k 0.6×	737 0.6×	524 0.9×	374 0.8×	17	2.2k
Gitanjali Srivastava United States	12	400 0.2×	367 0.2×	403 0.3×	229 0.4×	202 0.4×	37	1.1k
Cíntia Cercato Brazil	18	274 0.1×	362 0.2×	529 0.4×	226 0.4×	156 0.3×	54	1.3k
Tongzhi Wu Australia	32	248 0.1×	1.5k 0.8×	1.0k 0.8×	780 1.3×	705 1.4×	132	2.8k
Milan K. Piya United Kingdom	21	102 0.0×	483 0.3×	832 0.7×	310 0.5×	342 0.7×	74	1.8k
Pierre Maheux Canada	26	228 0.1×	1.5k 0.8×	660 0.5×	621 1.1×	412 0.8×	51	2.6k

Countries citing papers authored by Mark Boldrin

Since Specialization

Citations

This map shows the geographic impact of Mark Boldrin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Boldrin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Boldrin more than expected).

Fields of papers citing papers by Mark Boldrin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Boldrin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Boldrin. The network helps show where Mark Boldrin may publish in the future.

Co-authorship network of co-authors of Mark Boldrin

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Boldrin. A scholar is included among the top collaborators of Mark Boldrin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Boldrin. Mark Boldrin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhi, Jianguo, Suoping Zhai, & Mark Boldrin. (2016). Dose‐Dependent Effect of Piragliatin, a Glucokinase Activator, on the QT Interval Following Short‐Term Multiple Doses in Patients With Type 2 Diabetes Mellitus. Clinical Pharmacology in Drug Development. 6(3). 258–265. 5 indexed citations

Zhi, Jianguo, et al.. (2015). Exploratory effects of a strong CYP3A inhibitor (ketoconazole), a strong CYP3A inducer (rifampicin), and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients. The Journal of Clinical Pharmacology. 56(5). 548–554. 4 indexed citations

Zhai, Suoping, et al.. (2015). Lack of Potential Pharmacokinetic and Pharmacodynamic Interactions Between Piragliatin, a Glucokinase Activator, and Simvastatin in Patients With Type 2 Diabetes Mellitus. The Journal of Clinical Pharmacology. 56(6). 675–682. 4 indexed citations

Bergenstal, Richard M., Adriana Costa e Forti, Jean‐Louis Chiasson, et al.. (2012). Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial). Diabetes Therapy. 3(1). 13–13. 43 indexed citations

Nauck, Michael A., Edward S. Horton, Mirjana Andjelković, et al.. (2012). Taspoglutide, a once‐weekly glucagon‐like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open‐label randomized trial. Diabetic Medicine. 30(1). 109–113. 25 indexed citations

Raz, Itamar, Vivian Fonseca, Mark Kipnes, et al.. (2012). Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment. Diabetes Care. 35(3). 485–487. 32 indexed citations

Rosenstock, Julio, Bogdan Balas, B Charbonnel, et al.. (2012). The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes. Diabetes Care. 36(3). 498–504. 94 indexed citations

Pratley, Richard E., et al.. (2012). Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea‐metformin therapy: a randomized, double‐blind study (T‐emerge 6). Diabetes Obesity and Metabolism. 15(3). 234–240. 19 indexed citations

Ratner, Robert E., Michael A. Nauck, Christoph Kapitza, et al.. (2010). Safety and tolerability of high doses of taspoglutide, a once‐weekly human GLP‐1 analogue, in diabetic patients treated with metformin: a randomized double‐blind placebo‐controlled study^1,2. Diabetic Medicine. 27(5). 556–562. 37 indexed citations

10.

Nauck, Michael A., Robert E. Ratner, Christoph Kapitza, et al.. (2009). Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone. Diabetes Care. 32(7). 1237–1243. 100 indexed citations

11.

Chanoine, Jean‐Pierre, Sarah Hampl, Chad D. Jensen, Mark Boldrin, & Jonathan Hauptman. (2005). Effect of Orlistat on Weight and Body Composition in Obese Adolescents. A Randomized Controlled Trial. ACC Current Journal Review. 14(9). 7–7. 9 indexed citations

12.

Chanoine, Jean‐Pierre, Sarah Hampl, Craig L. Jensen, Mark Boldrin, & Jonathan Hauptman. (2005). Effect of Orlistat on Weight and Body Composition in Obese Adolescents. JAMA. 293(23). 2873–2873. 412 indexed citations

13.

Torgerson, Jarl, Jonathan Hauptman, Mark Boldrin, & Lars Sjöström. (2004). XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. Diabetes Care. 27(1). 155–161. 1284 indexed citations breakdown →

14.

Lucas, Charles, Mark Boldrin, & Gerald M. Reaven. (2003). Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. The American Journal of Cardiology. 91(8). 961–964. 37 indexed citations

15.

Guerciolini, Roberto, et al.. (2001). Comparative Evaluation of Fecal Fat Excretion Induced by Orlistat and Chitosan. Obesity Research. 9(6). 364–367. 52 indexed citations

16.

Reaven, Gerald M., Karen R. Segal, Jonathan Hauptman, Mark Boldrin, & Charles Lucas. (2001). Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. The American Journal of Cardiology. 87(7). 827–831. 77 indexed citations

17.

Hauptman, Jonathan, et al.. (2001). Orlistat in the Long-term Treatment of Obesity in Primary Care Settings.. Journal of Cardiopulmonary Rehabilitation. 21(1). 53–53. 1 indexed citations

18.

Heymsfield, Steven B., Karen R. Segal, Jonathan Hauptman, et al.. (2000). Effects of Weight Loss With Orlistat on Glucose Tolerance and Progression to Type 2 Diabetes in Obese Adults. Archives of Internal Medicine. 160(9). 1321–1321. 264 indexed citations

19.

Sjöström, Lars, A Rissanen, T Andersen, et al.. (2000). [Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients].. PubMed. 72(8). 50–4. 56 indexed citations

20.

Sjöström, Lars, Aila Rissanen, Teis Andersen, et al.. (1998). Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet. 352(9123). 167–172. 865 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact